Citius Pharmaceuticals Reports Strong Financial Growth in Q2 2026 with LYMPHIR Launch

Citius Pharmaceuticals Q2 2026 Financial Results

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a biopharmaceutical company renowned for its innovation in critical care products, has released its financial results for the second quarter of fiscal 2026, revealing impressive commercial progress mainly attributed to its subsidiary, Citius Oncology. The company's financial report, dated May 15, 2026, highlighted a noteworthy revenue of $5.6 million for the first half of the fiscal year 2026 stemming from the launch of its product, LYMPHIR, which has significantly impacted patient access and market penetration.

Financial Performance and Business Update

The report noted that since the launch of LYMPHIR in December 2025, Citius Oncology has achieved approximately 80% gross margins. By the end of the reporting period, 83% of target accounts had either approved or were actively reviewing LYMPHIR for formulary inclusion, while payer coverage has reached nearly 100% for covered commercial lives. Notably, no reimbursement denials have been reported, facilitating a smoother patient transition from academic cancer centers to local community infusion centers.

Leonard Mazur, the Chairman and CEO, emphasized the importance of these developments, particularly the comprehensive foundation of patient access that Citius Oncology has established to drive future growth. In a bid to further enhance its operational capacity, the company secured $36.5 million in debt and equity financing to support ongoing commercialization efforts and product supply.

Following the quarter's end, Citius Pharmaceuticals completed a registered direct offering, raising an additional $5 million to bolster its financial position and fund continued operational activities. The funds are earmarked for building out the LYMPHIR commercial field force by mid-summer, thereby enhancing physician engagement and broadening market penetration.

Progress in Research and Development

In addition to commercial achievements, Citius Pharmaceuticals announced positive preliminary data from two Phase 1 studies involving LYMPHIR combined with pembrolizumab and CAR-T therapy. The results of these studies reinforce the potential of LYMPHIR as a cornerstone in combination therapy regimens, opening avenues for further development within oncology.

The company remains committed to advancing innovative therapeutic solutions, including its other projects such as Mino-Lok and Halo-Lido. Ongoing communications with the FDA regarding these initiatives highlight the organization’s focus on compliance and operational excellence.

Fiscal Highlights

Citius reported cash and cash equivalents of $4.6 million as of March 31, 2026. The company's net revenues were $1.67 million for the quarter, a significant increase compared to the same period in the previous year, which reported no revenue. Additionally, gross profit for this quarter reached $1.3 million, indicative of the robust market response to LYMPHIR.

The operating expenses for the quarter were approximately $33.5 million, with a notable portion attributed to general and administrative expenses primarily driven by a one-time charge related to a contract cancellation. Despite these costs, Citius has reported a net loss of $21.2 million for the quarter, demonstrating the company’s focused investment in its growth trajectory.

Mazur concluded with optimism regarding the future, indicating that, given the current financial momentum and operational strategies, the company is well-positioned for sustained growth and success in its endeavors within the oncology sector and beyond.

Conclusion

Citius Pharmaceuticals continues to make strides within the biopharmaceutical landscape, demonstrating resilience and commitment to enhancing patient access to critical care treatments. The company’s ongoing work with LYMPHIR not only emphasizes its potential within cancer therapy but also solidifies Citius’s position as an innovative force in the market. Investors and stakeholders are encouraged to keep an eye on the company as it navigates these developments and seeks to capitalize on its recent successes.